Ozempic eligibility in Nepal — who can take semaglutide, BMI criteria (Asian cut-offs), required tests, and who should not take it. Doctor-assessed candidacy at Stree Clinic, Durbarmarg.
Ozempic eligibility in summary: weight-management criteria BMI ≥30 or ≥27 with a weight-related comorbidity; diabetes indication driven by glycemic need; exclusions for MTC/MEN2 history, serious hypersensitivity, pregnancy and breastfeeding; cautions for pancreatitis, severe GI disease, retinopathy and combination diabetes therapy. Final eligibility is a doctor's decision after labs and history.
Ozempic program | Nepal treatment guide | FAQs | What is Ozempic? | Dosage | Who should avoid | Drug interactions | Monitoring | Results | Vs Wegovy vs Mounjaro | Diet & exercise | Price in Nepal | Stree Clinic | Lead Doctor | Weight loss | Diabetes care | Side effects | Success stories | Editorial policy | How to get Ozempic | Results timeline | Meal plan | Injection guide | Storage & cold chain | Myths vs facts | नेपालीमा | Conditions treated | Clinical trials | BMI eligibility | BMI calculator | Without diabetes | Fake semaglutide warning | Ozempic & alcohol | Vs Saxenda | PCOS | Fatty liver | Kidney disease | Prediabetes | Heart health | Alternatives | Ozempic face | Hair loss | Stopping Ozempic | For men | For women | Not losing weight | Semaglutide in Nepal | GLP-1 treatment | Find a doctor | Availability | Medical weight loss | Obesity treatment | Diabetes doctor | Insulin resistance | Wegovy in Nepal | Mounjaro in Nepal | Rybelsus in Nepal | Areas served | Find a specialist | Weight loss medication | Book consultation | Ozempic vs keto | Vs low-carb | Vs calorie deficit | Vs exercise | Vs diet & exercise | Vs intermittent fasting | Vs fasting | Vs natural weight loss | Vs lifestyle changes | Vs medical weight mgmt | Vs dietitian-guided | Vs bariatric surgery | Request assessment
Adults with type 2 diabetes needing better control, or adults with overweight/obesity where a doctor judges GLP-1 therapy appropriate — typically BMI ≥27.5 (Asian cut-off) with a weight-related condition, or ≥30 without. Eligibility is confirmed by doctor assessment, not self-diagnosis.
For weight management, guidelines use BMI ≥30, or ≥27 with a weight-related condition (diabetes, hypertension, sleep apnea, fatty liver). For Asian populations including Nepalis, cut-offs are lower (≥27.5 for obesity). Your doctor assesses the full picture, not BMI alone.
People with personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, or serious semaglutide allergy. Also avoid in pregnancy/breastfeeding, and use caution with pancreatitis history, severe GI disease, or kidney issues — your doctor screens for all of these.
Baseline work includes: blood sugar/HbA1c, kidney function, liver enzymes, thyroid markers, and sometimes lipid panel and pregnancy test. Tests come first — they determine eligibility and catch conditions that change the treatment plan.
No — Ozempic is approved for type 2 diabetes, but doctors may prescribe semaglutide for weight management based on your case (the same molecule at higher dose is approved as Wegovy). Eligibility is a medical decision, not a diabetes-only rule.
Start with our free assessment form at ramrodoctor.com/ozempic/assessment — it captures your basics for the medical team to review. But final eligibility always requires lab tests and an in-person doctor consultation at Stree Clinic, Kathmandu.
Browse all pages